The Journal of Allergy and Clinical Immunology
Volume 122, Issue 4 , Pages 671-682, October 2008

Host immune responses to rhinovirus: Mechanisms in asthma

  • John T. Kelly, MD
  • ,
  • William W. Busse, MD

      Affiliations

    • Corresponding Author InformationReprint requests: William W. Busse, MD, University of Wisconsin School of Medicine and Public Health, Department of Allergy and Clinical Immunology, J5/219 CSC, Box 2454, 600 Highland Ave, Madison, WI 53792.

Received 10 July 2008; received in revised form 15 August 2008; accepted 18 August 2008.

Viral respiratory infections can have a profound effect on many aspects of asthma including its inception, exacerbations, and, possibly, severity. Of the many viral respiratory infections that influence asthma, the common cold virus, rhinovirus, has emerged as the most frequent illness associated with exacerbations and other aspects of asthma. The mechanisms by which rhinovirus influences asthma are not fully established, but current evidence indicates that the immune response to this virus is critical in this process. Many airway cell types are involved in the immune response to rhinovirus, but most important are respiratory epithelial cells and possibly macrophages. Infection of epithelial cells generates a variety of proinflammatory mediators to attract inflammatory cells to the airway with a subsequent worsening of underlying disease. Furthermore, there is evidence that the epithelial airway antiviral response to rhinovirus may be defective in asthma. Therefore, understanding the immune response to rhinovirus is a key step in defining mechanisms of asthma, exacerbations, and, perhaps most importantly, improved treatment.

Key words: Asthma, exacerbation, rhinovirus, immune response to virus, pathogenesis

Abbreviations used: EC, Epithelial cell, ICAM-1, Intercellular adhesion molecule 1, ICS, Inhaled corticosteroid, IP, Inducible protein, LT, Leukotriene, MIP, Macrophage inflammatory protein, RANTES, Regulated upon activation, normal T-cell expressed and secreted, RSV, Respiratory syncytial virus

 

 (Supported by an educational grant from Merck & Co., Inc.)

 Series editors: Joshua A. Boyce, MD, Fred Finkelman, MD, William T. Shearer, MD, PhD, and Donata Vercelli, MD

 Supported by National Institutes of Health–National Heart, Lung, and Blood Institute grant no. HL069116 and National Institutes of Health–National Institute of Allergy and Infectious Diseases grant no. T32 AI007635.

 Terms in boldface and italics are defined in the glossary on page 672.

PII: S0091-6749(08)01506-6

doi:10.1016/j.jaci.2008.08.013

The Journal of Allergy and Clinical Immunology
Volume 122, Issue 4 , Pages 671-682, October 2008